NCT05589896View on ClinicalTrials.gov

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

February 25, 2026

Study Completion Date

December 31, 2026

Conditions
Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Undifferentiated LeukemiaCLL (Chronic Lymphocytic Leukemia)Chronic Myeloid Leukemia (CML)MDS (Myelodysplastic Syndrome)Non-Hodgkin LymphomasHodgkins LymphomaCutaneous T Cell Lymphomas (CTCL)
Interventions
OTHER

Ossium HPC Marrow, Bone Marrow Transplant

Hematopoetic Cell Transplantation

OTHER

Pre-transplant conditioning - Myeloablative (MAC)

Regimen A or Regimen B

OTHER

Pre-transplant conditioning - Reduced Intensity (RIC)

Regimen C or Regimen D

OTHER

Post-transplant treatment

Post-transplant treatment

Trial Locations (9)

10032

RECRUITING

Columbia University - Herbert Irving Comprehensive Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

TriStar Bone Marrow Transplant, Nashville

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

78229

RECRUITING

Methodist Hospital, Texas Transplant, San Antonio

78745

RECRUITING

St. David's South Austin Medical Center, Austin

84112

RECRUITING

University of Utah - Huntsman Cancer Institute, Salt Lake City

91010

RECRUITING

City of Hope, Duarte

97239

RECRUITING

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
collaborator

Center for International Blood and Marrow Transplant Research

NETWORK

lead

Ossium Health, Inc.

INDUSTRY

NCT05589896 - A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter